Particle.news
Download on the App Store
6 ARTICLES
·
2w ago

Sept. 30 Lead‑Plaintiff Deadline Nears in Novo Nordisk Securities Case

The filing window follows the July 29 cut to 2025 sales guidance for Wegovy and Ozempic that sent the ADR down 21.8%.

Nvo deadline: rosen, global investor counsel, encourages novo nordisk a/s investors to secure counsel before important september 30 deadline in securities class action nvo

Overview

  • A class action has been filed covering purchases of Novo Nordisk securities between May 7 and July 28, 2025, with September 30, 2025 set as the deadline to seek appointment as lead plaintiff.
  • Plaintiffs allege the company misled investors about growth prospects in GLP‑1 therapies, including understating the personalization exception’s impact on compounded products and overstating the likelihood of switching to branded drugs.
  • On July 29, 2025, Novo Nordisk lowered its full‑year outlook, citing persistent use of compounded GLP‑1s, slower market expansion, and competition.
  • Following the guidance cut, the ADR closed at $53.94 on July 29, 2025, down $15.06 or 21.83% from the prior session.
  • Rosen Law Firm, Pomerantz LLP, and Faruqi & Faruqi are urging eligible investors to contact them, and they note that no class has been certified and the allegations remain unproven.